Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
Aug 15, 2023
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
Jun 06, 2023
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
Jun 05, 2023
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
May 25, 2023
We focus on serious and intractable diseases to help patients around the world.
We are technology agnostic in targeting hematologic malignancies and solid tumors. We are exploring 4 different technologies to help treat disease.
Our leaders bring significant expertise from some of the world’s largest pharma companies.
We are an end-to-end cell therapy company. Our capabilities extend from discovery to commercialization.
We offer a variety of career choices that support the development of novel therapies.
Our pipeline is comprised of investigational agents and innovative technologies in personalized medicine. We are devoted to exploring the potential of cell therapies to treat diseases that are considered intractable and incurable, including hematological malignancies and solid tumors.